Windtree to Present at the H.C. Wainwright Global Life Sciences Conference
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The company focuses on advancing late-stage interventions for acute cardiovascular and pulmonary disorders, including istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A live audio webcast will be available on the company's website, with a replay for 30 days. For further details, visit www.windtreetx.com.
Details
News Market Reaction – WINT
The recorded move for WINT in the trading session of this news was +8.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARRINGTON, Pa., March 8, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference and be available for 1x1 meetings. Details are as follows:
H.C. Wainwright Global Life Sciences Conference | |
Date: | March 9-10, 2021 |
Time: | available for 1x1 meetings |
Webcast: | To register, click on the link HERE |
A live audio webcast will be available via the events page of the Windtree website at http://windtreetx.investorroom.com/events. A replay of the presentation will be archived on the Windtree website for 30 days for those unable to listen live.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
For more information, please visit the Company's website at www.windtreetx.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/windtree-to-present-at-the-hc-wainwright-global-life-sciences-conference-301241442.html
SOURCE Windtree Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.